Novo Nordisk's next gen obesity drug CagriSema outperforms Wegovy in late stage diabetes trial : r mounjarouk Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Novo Nordisk shares slide despite promising weight loss trial results Sharecast.com Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet